M-43 is a recombinant analogue of fibroblast growth factor-1 (FGF-1) that has been previously shown to bind the insulin receptor (InsR), activate insulin-like cellular signaling and reduce insulin resistance. Researchers from Celon Pharma SP have recently presented results on the efficacy of the candidate as assessed in Zucker diabetic fatty (ZDF) rats.
Scholar Rock Inc. has announced plans to advance SRK-439, a novel investigational myostatin inhibitor for the treatment of obesity, toward an IND submission in 2025.
A team from Atrogi AB has reported the activity of ATR-127, a novel dual adrenergic agonist targeting β2- and β3-adrenoceptors (ARs), for the potential treatment of steatohepatitis, obesity and diabetes.
Researchers from Yuhan Corp. presented the discovery and preclinical evaluation of a novel long-acting dual agonist of the glucagon like peptide-1 (GLP-1) and growth differentiation factor 15 (GDF-15), YH-40863.
The ALDH2 gene encodes mitochondrial aldehyde dehydrogenase 2 (ALDH2), a major acetaldehyde-metabolizing enzyme. Approximately 36% of East Asians (around 560 million people) carry an inactivating E504K missense mutation of the ALDH2 gene, which reduces ALDH2 enzymatic activity. This inactivating mutation has been correlated with several diseases and is strongly associated with type 2 diabetes, body mass index and serum lipids in East Asians.
Researchers from the Universities of Malaga and Cordoba (Spain) presented data from a study that aimed to identify matrisome regulator miRNAs in obesity and prediabetes that could represent novel noninvasive circulating biomarkers of adipose tissue (AT) fibrosis.
Obesity is a chronic disease caused by the concurrence of genetics and environmental and individual behaviors that lead to an imbalance between caloric intake and expenditure and are linked to increased mortality and morbidity.
Researchers from East China Normal University and Shanghai Jiao Tong University presented the discovery and preclinical evaluation of new potent antiosteoporosis agents. Synthesis and optimization of a series of heterocyclic ring-fused derivatives of 20(S)-protopanaxadiol (PPD) led to the identification of SH-491 as the lead candidate with the most potent inhibitory effects on RANKL-induced osteoclastogenesis (IC50=11.8 nM).
Sab Biotherapeutics Inc. has announced a private placement of up to $130 to fund the company’s lead research program, SAB-142, a potential disease-modifying treatment for type 1 diabetes. SAB-142 is expected to advance into clinical trials in the fourth quarter of this year.
Fudan University has patented compounds acting as microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B) inhibitors and proprotein convertase subtilisin/kexin-type 9 (PCSK9) degradation inducers reported to be useful for the treatment of alopecia, atherosclerosis, cancer, Alzheimer’s disease, pulmonary fibrosis, hyperlipidemia, keratosis and obesity, among others.
RSS
